ID: ALA381394

Max Phase: Preclinical

Molecular Formula: C28H37N5O7

Molecular Weight: 555.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)Nc2c(C)noc2C)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C28H37N5O7/c1-7-8-14-20(22(34)24(35)29-16(2)19-12-10-9-11-13-19)30-27(38)39-23-25(36)33(15-28(23,5)6)26(37)31-21-17(3)32-40-18(21)4/h9-13,16,20,23H,7-8,14-15H2,1-6H3,(H,29,35)(H,30,38)(H,31,37)/t16-,20+,23-/m1/s1

Standard InChI Key:  JBAPSUGYURPCRH-NIJIEXERSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 555.63

Molecular Weight (Monoisotopic): 555.2693

AlogP: 3.79

#Rotatable Bonds: 10

Polar Surface Area: 159.94

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 8.90

CX Basic pKa: 1.01

CX LogP: 3.68

CX LogD: 3.66

Aromatic Rings: 2

Heavy Atoms: 40

QED Weighted: 0.37

Np Likeness Score: -0.66

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature